EUZIRI
Live / Applied — Fourth extension granted (statement of use) (as of 30 May 2025)
What this means for you
Not registered yet, but its 12 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97500313
- Mark type
- Stylized text
- Filed
- 12 Jul 2022
- Published for opposition
- 30 May 2023
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 15 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 May 2025 — SOU EXTENSION 4 GRANTED
- 30 May 2025 — SOU EXTENSION 4 FILED
- 30 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jan 2025 — SOU EXTENSION 3 GRANTED
- 10 Jan 2025 — SOU EXTENSION 3 FILED
- 10 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jul 2024 — SOU EXTENSION 2 GRANTED
- 01 Jul 2024 — SOU EXTENSION 2 FILED
- 01 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 18 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jan 2024 — SOU EXTENSION 1 GRANTED